期刊文献+

来氟米特联合糖皮质激素治疗IgA肾病疗效观察 被引量:22

Effect of leflunomide plus glucocorticoids on IgA nephropathy
原文传递
导出
摘要 目的观察来氟米特联合糖皮质激素治疗IgA肾病的疗效和安全性。方法 IgA肾病患者60例,随机分为治疗组和对照组各30例,治疗组给予醋酸泼尼松联合来氟米特片口服;对照组仅给予醋酸泼尼松片口服,用法、用量同治疗组;2组疗程均为12个月。分别于治疗前及治疗后1、3、6、12个月测定2组24h尿蛋白定量、血浆白蛋白、血清肌酐、收缩压、舒张压水平,并比较2组疗效和不良反应发生情况。结果治疗后12个月,治疗组总有效率(93.3%)高于对照组(70.0%)(P<0.05),2组完全缓解率、不良反应发生率比较差异无统计学意义(P>0.05);治疗前及治疗后各时间点,2组血清肌酐、收缩压及舒张压比较差异无统计学意义(P>0.05);治疗组治疗后3、6、12个月,对照组治疗后6、12个月24h尿蛋白定量与白蛋白水平与治疗前比较差异有统计学意义(P<0.05);治疗后12个月,治疗组24h尿蛋白定量水平低于对照组,白蛋白水平高于对照组(P<0.05)。结论来氟米特联合糖皮质激素在减少IgA肾病尿蛋白,升高血浆白蛋白水平上优于单用糖皮质激素。 Objective To explore the therapeutic effect and safety of leflunomide plus glucocorticoid in the treatment of IgA nephropathy. Methods Sixty patients with IgA nephropathy were randomly divided into two groups: treatment group and control group, with 30 patients in each group. Treatment group was given oral administration of leflunomide plus prednisone, and control group was given only prednisone orally with the same dose as tratment group, totally for 12 months. The levels of 24-hour urine protein, plasma albumin, serum creatinine, systolic blood pressure and diastolic blood pressure were detected before treatment and 1, 3, 6 and 12 months after treatment. The therapeutic effect and adverse reactions were compared between two groups. Results After 12 months of treatment, the total effective rate was 93.3% in treatment group, higher than that in control group (70. 0%) (P〈C0.05), and there were no significant differences in complete remission rate and incidence of adverse reactions between two groups. Serum creatinine level, systolic blood pressure and diastolic blood pressure showed no significant differences in both two groups after treatment in comparison with before treatment (P〉0. 05). There were significant differences in 24 hour urine protein and plasma albumin levels in 3, 6 and 12 months after treatment in treatment group and in 6 and 12 months after treatment in control group in comparison with before treatment (P〈0.05). In 12 months after treatment, 24-hour urine protein level was lower and plasma albumin level was higher in treatment group than that in control group (P〈0.05). Conclusions Leflunomide plus glucocorticoid is more effective for reducing urine protein and increasing albumin than glucocorticoid in the treatment of IgA nephropathy.
出处 《中华实用诊断与治疗杂志》 2014年第5期504-506,共3页 Journal of Chinese Practical Diagnosis and Therapy
关键词 IGA肾病 来氟米特 糖皮质激素 IgA nephropathy leflunomide glucocorticoid
  • 相关文献

参考文献12

  • 1Berthoux F C, Mohey H, Afiani A. Natural history of primary IgA nephropathy[J]. Semin Nephrol,2008,28(1) :4-9.
  • 2Lee S M, Rao V M, Franklin W A, et al. IgA nephropathy: morphologie predictors of progressive renal disease[J]. Hum Pathol, 1982,13(4) : 314-322.
  • 3陈香美,陈仆,蔡广研,吴杰,崔岩,张燕平,刘述文,汤力.麦考酚酸酯治疗IgA肾病的随访对照观察[J].中华医学杂志,2002,82(12):796-801. 被引量:93
  • 4王海燕.肾脏病学[M].3版.北京:人民卫生出版社,2008:8262.
  • 5Reich H N, Troyanov S, Scholey J W, et al. Remission of proteinuria improves prognosis in IgA nephropathy[J]. J Am Soc Nephrol,2007,18(12) :3177-3183.
  • 6Donadio J V, Grande J P. IgA nephropathy[J]. N Engl J Med, 2002,347(10) :738-748.
  • 7Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long term results of a randomized, controlled trial[J]. J Am Soc Nephrol, 2004, 15 (1) :157-163.
  • 8Manno C, Torres D D, Rossini M, etal. Randomized controlled clinical trial of eorticosteroids plus ACEqnhibitors with long term follow-up in proteinuric IgA nephropathy[J]. Nephrol Dial Transplant,2009,24(12) :3694 -3701.
  • 9Imose M, Nagki M, Kimura K, et al. I.eflunomide protects from T-cell-mediated liver injury in mice through inhibition of nuclear factor kappaB[J]. Hepatology,2004,40(5) : 1160-1169.
  • 10黄清河,郭汉城,姚春萌.来氟米特对糖尿病大鼠肾脏病理及NF-κB活化的影响[J].中国中西医结合肾病杂志,2010,11(2):149-150. 被引量:4

二级参考文献22

  • 1李雄根,贺晓蕾,沈倍义,陈化蓉,张欣洲,易铁刚.来氟米特治疗以肾病综合征为主的IgA肾病临床分析[J].河北医学,2005,11(6):501-502. 被引量:3
  • 2张杰,何俊,李正良,申兵冰,刘先蓉,沙朝晖,钟慧,夏妮娅,黄颂敏.来氟米特治疗IgA肾病的临床研究[J].中国实用内科杂志,2005,25(7):628-630. 被引量:25
  • 3赵珉,张伯科,王坤,钱浩,戴宏,梁维龙,阚春明.来氟米特对大鼠肾毒血清性肾炎早期肾损害的保护作用[J].安徽医科大学学报,2006,41(3):290-293. 被引量:6
  • 4王成,娄探奇,彭晖,刘迅,陈珠江,唐骅,余学清.来氟米特联合泼尼松治疗难治性原发性肾病综合征的随机对照试验[J].中国新药与临床杂志,2006,25(12):889-892. 被引量:27
  • 5Katherine RT.Linking metabolism and immunology:diabetic Nephropathy is an inflammatory disease.J Am Soc Nephrol,2005,16(6):1537-1538.
  • 6Noronha IL,Fujihara CK,Zatz R.The inflammatory component in progressive renal disease-are interventions possible.Nephrol Dial Transplant,2002,17(3):363-368.
  • 7Utimura R,Fujihara CK,Mattar AL,et al.Mycophemolate mofetil prevents the development of glomerular injury in experimental diabetes.Kidney Int,2003,63(1):209-216.
  • 8Kikuchi Y,Kobayasbi S,Hemmi N,et al.Galectin-3-positive cell infiltration in human diabetic nephropathy.Nephrol Dial Transplant,2004,19(3):602-607.
  • 9Hofmann MA,Schiekofer S,Isermann B,et al.Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-kappaB.Diabetologia,1999,42 (2):222-232.
  • 10du Buf-Vereijken P W, Branten A J, Wetzels J F, et al. Cytotoxic therapy for membranous nephropathy and renal insufficiency, improved renal survival but high relapse rate[J]. Nephrol Dial Transplant, 2004,19(5) : 1142-1148.

共引文献596

同被引文献161

引证文献22

二级引证文献97

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部